Sentences with phrase «multiple myeloma patients»

Half of multiple myeloma patients diagnosed in the earliest stage of the disease don't survive beyond about five years after initial treatment because the cancer becomes resistant to treatments.

Figure on the right: Bortezomib treatment is significantly less effective in multiple myeloma patients who have suppressed expression of a 19s proteasome cap subunit.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.

Furthermore, the levels of Runx2 expression among a larger group of 351 newly diagnosed multiple myeloma patients were significantly higher in patients who had a high risk of early disease - related death, as compared with lower - risk patients.

Using a database of multiple myeloma patient samples and information, researchers at University of California San Diego School of Medicine found that high ADAR1 levels correlate with reduced survival rates.

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

Initial treatment for most multiple myeloma patients includes a class of drugs (Revlimid or Pomalyst) broadly known as immune modulators.

«Multiple myeloma patient study shows promise for natural killer cells: Phase I study included combination with high - dose chemotherapy and stem cell transplantation.»

To unravel exactly how ADAR1 is connected to disease severity at a molecular level, the researchers transferred multiple myeloma patient tissue to mice, creating what's known as a xenograft or «humanized» model.

«African - American multiple myeloma patients have higher incidence rates and lower survival rates than their Caucasian peers despite this being a relatively easy - to - treat cancer.

A first - in - human Phase I study of multiple myeloma patients combined expanded cord blood - derived natural killer cells with transplantation of a patient's own stem cells and high - dose chemotherapy with little or none of the side effects seen with current treatments.

The combination of pomalidomide plus low - dose dexamethasone showed efficacy with high rates of disease control in relapsed or refractory multiple myeloma patients with severe renal impairment, according to the results of a phase II study.

Analyzing a database of nearly 800 multiple myeloma patient samples, they discovered that 162 patients with low ADAR1 levels in their tumor cells survived significantly longer over a three - year period compared to 159 patients with high ADAR1 levels.

Most multiple myeloma patients, however, are ineligible for allogeneic transplantation due to age and medical restrictions.

«Personalized drug screening on horizon for multiple myeloma patients.»

While some previous studies found that maintenance lenalidomide after autologous hematopoietic stem cell transplant improved overall survival for newly diagnosed multiple myeloma patients, others showed no benefit to this approach.

«Choice of medical center impacts life expectancy of multiple myeloma patients, study shows.»

Thirty to 50 percent of multiple myeloma patients have extra copies of the gene that encodes the enzyme ADAR1.

In humans, a comparison of bone marrow from 14 normal bone marrow donors, 35 multiple myeloma patients and 11 patients with a noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher in the multiple myeloma cells.

For example, in the study, multiple myeloma patients of European descent were six times more likely than their African peers to have mutations in the TP53 gene, a tumor suppressor that helps prevent cancer.

Researchers analyzed the genetic sequencing data of 718 multiple myeloma patients and found that African - Americans had increased mutations in the genes BCL7A, BRWD3 and AUTS2, while white people had more mutations in the genes TP53 and IRF4.

«The drug, LCL161, was initially developed to promote tumor death,» says Marta Chesi, Ph.D., a Mayo Clinic biochemist and lead author of the study of 25 Multiple Myeloma patients.

A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.

Richard Vague, the event's honorary chair, took the podium to acknowledge the vast achievements of the ACC, as did Lori Alf, a multiple myeloma patient of Edward Stadtmauer, MD, chief of Hematologic Malignancies, whose cancer is in remission after receiving chimeric antigen receptor (CAR) therapy.

The current study, which has accrued 32 patients to date, is the first in - human study of daratumumab in multiple myeloma patients.

The only documented long - term complete remissions reported in multiple myeloma patients have occurred with allogeneic bone marrow transplantation, where a donor's blood stem cells (graft) are transplanted into the patient (host) with multiple myeloma.

This page features information on multiple myeloma and immunotherapy clinical trials for multiple myeloma patients, and highlights the Cancer Research Institute's role in working to bring effective immune - based cancer treatments to people with multiple myeloma.

PHILADELPHIA — A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.

Darbepoietin - Alfa after High - Dose Melphalan and Autologous Hemopoietic Progenitor Cell in Multiple Myeloma Patients: A Pilot Study